Toujeo

Insulin glargine

Treatment of DM in adults, adolescents & childn ≥6 yr.

SC Type 1 DM Once-daily w/ meal-time insulin & requires individual dose adjustments. Must be combined w/ short-/rapid-acting insulin to cover mealtime insulin requirements. Type 2 DM Initially 0.2 u/kg followed by individual dose adjustments. May also be given w/ other anti-hyperglycaemic products.

Hypersensitivity.

Not for diabetic ketoacidosis. Patients in whom hypoglycaemic episodes might be of particular clinical relevance eg, those w/ significant stenoses of coronary arteries or of blood vessels supplying the brain, & proliferative retinopathy particularly if not treated w/ photocoagulation. Patients w/ diminished warning symptoms of hypoglycaemia eg, those w/ marked improvement in glycaemic control, w/ gradual development of hypoglycaemia, elderly, after transfer from animal to human insulin, w/ autonomic neuropathy, long history of diabetes, psychiatric illness. Closely monitor patients & adjust dose, if necessary, in case of factors that increase susceptibility to hypoglycaemia eg, change in inj area, improved insulin sensitivity (eg, by removal of stress factors), unaccustomed, increased or prolonged physical activity, intercurrent illness (eg, vomiting, diarrhoea), inadequate food intake, missed meals, alcohol consumption, certain uncompensated endocrine disorders (eg, in hypothyroidism & in anterior pituitary or adrenocortical insufficiency). Intercurrent illness requires intensified metabolic monitoring. May cause insulin Abs to form. Switching between insulin glargine 100 u/mL & Toujeo; switching between other insulins & Toujeo. Cases of cardiac failure w/ pioglitazone. Concomitant use w/ other medicines. May impair ability to concentrate & react when driving a car or using machines. Patients w/ renal & hepatic impairment. Pregnancy & lactation. Childn <6 yr. Elderly ≥65 yr.

Hypoglycaemia. Lipohypertrophy; inj site reactions.

Enhanced blood-glucose-lowering effect & increased susceptibility to hypoglycaemia w/ anti-hyperglycaemics, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulfonamide antibiotics. Reduced blood-glucose-lowering effect w/ corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine & olanzapine) & PIs. Potentiated or weakened blood-glucose-lowering effect w/ β-blockers, clonidine, lithium salts or alcohol. Pentamidine may cause hypoglycaemia (which may sometimes be followed by hyperglycaemia). Reduced or absent signs of adrenergic counter-regulation w/ sympatholytics eg, β-blockers, clonidine, guanethidine & reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

P₁